Xilio Therapeutics (XLO) is currently trading at $1.04, near the lower end of its 52-week range ($0.49-$2.04). Despite a "Moderate Buy" consensus from analysts, the stock's bearish outlook stems from its limited cash runway, which is expected to last only until Q2 2025, and its negative P/E ratio (-0.41), reflecting ongoing losses. The price could drop further if no significant clinical or financial breakthroughs occur soon.